辅助性与进展时伽玛刀放射外科治疗残留无功能垂体腺瘤的匹配队列分析
这项回顾性多中心研究纳入375例残留无功能垂体腺瘤(NFPA)患者,比较辅助性(ADJ,术后6个月内治疗稳定残留)与进展时(PRG)立体定向放射外科(SRS)的时机。倾向评分匹配后每组130例,末次随访肿瘤控制率ADJ组93.1% vs PRG组96.2%(HR 1.6,95%CI 0.55-4.9,p=0.37),新发垂体功能减退与视觉缺损粗率无统计学显著差异,PRG组新发垂体功能减退中位时间长于ADJ组(58.9 vs 29.7个月,p=0.01)。
要点
- 匹配后ADJ组与PRG组肿瘤控制率分别为93.1%与96.2%,差异无统计学显著(HR 1.6,95%CI 0.55-4.9,p=0.37)。
- 垂体柄最大点剂量>8 Gy与垂体功能减退相关(HR 4.5,95%CI 1.6-12.6,p=0.004)。
- PRG组新发垂体功能减退中位时间58.9个月,长于ADJ组的29.7个月(p=0.01)。
核心结论
- 与辅助性SRS相比,在残留NFPA进展时行SRS似乎不改变肿瘤控制或激素/视觉缺损的概率。
- 将放射外科推迟至影像学进展时可能显著延长放射外科所致垂体功能障碍的发生时间。
- 垂体柄最大点剂量较低(<8 Gy)预示SRS后保留垂体功能的机会更有利。
研究设计与样本
- 回顾性多中心研究,纳入375例接受SRS治疗的残留无功能垂体腺瘤患者。
- 患者分为辅助组(ADJ,术后6个月内针对稳定残留NFPA治疗)与进展组(PRG,针对残留NFPA进展治疗)。
- 倾向评分匹配后每组各130例。
- 分析肿瘤进展与临床恶化相关因素。
主要发现
- 末次随访肿瘤控制率ADJ组93.1% vs PRG组96.2%(HR 1.6,95%CI 0.55-4.9,p=0.37)。
- 垂体功能减退与垂体柄最大点剂量>8 Gy相关(HR 4.5,95%CI 1.6-12.6,p=0.004)。
- 末次随访两组新发垂体功能减退粗率无统计学显著差异(风险差RD=-0.8%,p>0.99)。
- 末次随访两组视觉缺损无统计学显著差异(RD=-2.3%,p=0.21)。
- 新发垂体功能减退的中位时间PRG组58.9个月 vs ADJ组29.7个月(p=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Radiological progression occurs in 50%-60% of residual nonfunctioning pituitary adenomas (NFPAs). Stereotactic radiosurgery (SRS) is a safe and effective management option for residual NFPAs, but there is no consensus on its optimal timing. This study aims to define the optimal timing of SRS for residual NFPAs. METHODS: This retrospective, multicenter study involved 375 patients with residual NFPAs managed with SRS. The patients were divided into adjuvant (ADJ; treated for stable residual NFPA within 6 months of resection) and progression (PRG) cohorts (treated for residual NFPA progression). Factors associated with tumor progression and clinical deterioration were analyzed. RESULTS: Following propensity-score matching, each cohort consisted of 130 patients. At last follow-up, tumor control was achieved in 93.1% of patients in the ADJ cohort and in 96.2% of patients in the PRG cohort (HR 1.6, 95% CI 0.55-4.9, p = 0.37). Hypopituitarism was associated with a maximum point dose of > 8 Gy to the pituitary stalk (HR 4.5, 95% CI 1.6-12.6, p = 0.004). No statistically significant difference was noted in crude new-onset hypopituitarism rates (risk difference [RD] = -0.8%, p > 0.99) or visual deficits (RD = -2.3%, p = 0.21) between the two cohorts at the last follow-up. The median time from resection to new hypopituitarism was longer in the PRG cohort (58.9 vs 29.7 months, p = 0.01). CONCLUSIONS: SRS at residual NFPA progression does not appear to alter the probability of tumor control or hormonal/visual deficits compared with adjuvant SRS. Deferral of radiosurgical management to the time of radiological progression could significantly prolong the time to radiosurgically induced pituitary dysfunction. A lower maximum point dose (< 8 Gy) to the pituitary stalk portended a more favorable chance of preserving pituitary function after SRS.
引用
- Mantziaris G, Pikis S, Chytka T, et al. Adjuvant versus on-progression Gamma Knife radiosurgery for residual nonfunctioning pituitary adenomas: a matched-cohort analysis. J Neurosurg. 2022. PMID: 36401547. doi:10.3171/2022.10.JNS221873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。